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The PML/RARA fusion protein occurs as a result of the t(15;17)translocation in the acute promyelocytic leukemia subtype ofhuman acute myeloid leukemia. Gain of chromosome 8 is the
most common chromosomal gain in human acute myeloid leukemia,
including acute promyelocytic leukemia. We previously demonstrated
that gain of chromosome 8-containing MYC is of central importance in
trisomy 8, but the role of the nearby TRIB1 gene has not been experi-
mentally addressed in this context. We have now tested the hypothesis
that both MYC and TRIB1 have functional roles underlying leukemoge-
nesis of trisomy 8 by using retroviral vectors to express MYC and TRIB1
in wild-type bone marrow and in marrow that expressed a PML/RARA
transgene. Interestingly, although MYC and TRIB1 readily co-operated
in leukemogenesis for wild-type bone marrow, TRIB1 provided no
selective advantage to cells expressing PML/RARA. We hypothesized
that this lack of co-operation between PML/RARA and TRIB1 reflected
a common pathway for their effect: both proteins targeting the myeloid
transcription factor C/EBPα. In support of this idea, TRIB1 expression
abrogated the all-trans retinoic acid response of acute promyelocytic
leukemia cells in vitro and in vivo. Our data delineate the common and
redundant inhibitory effects of TRIB1 and PML/RARA on C/EBPα pro-
viding a potential explanation for the lack of selection of TRIB1 in
human acute promyelocytic leukemia, and highlighting the key role of
C/EBPs in acute promyelocytic leukemia pathogenesis and therapeutic
response. In addition, the co-operativity we observed between MYC
and TRIB1 in the absence of PML/RARA show that, outside of acute
promyelocytic leukemia, gain of both genes may drive selection for tri-
somy 8.
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ABSTRACT
Introduction
Acute myeloid leukemia (AML) is the most common
leukemia subtype in adults representing 80% of cases for
a worldwide incidence of 3.8/100,000 cases per year.1 The
relapse risk for AML remains unacceptably high and
relapse is the most common cause of death. Multiple
courses of chemotherapy including combinations of
anthracycline and cytarabine remain the mainstay of treat-
ment but a ceiling of benefit has been reached and toxicity
is significant. One particular exception is patients with
acute promyelocytic leukemia (APL), a distinctive subtype
representing 5%-15% of AML cases.2 APL patients typical-
ly express the PML/RARA fusion protein as a result of a
t(15;17)(q22;q12) translocation, which renders cells
exquisitely sensitive to all-trans retinoic acid (ATRA) lead-
ing to remission in the majority of cases.3 APL is character-
ized by clonal proliferation of myeloid blasts that have lost
their differentiation capacity, and ATRA is thought to
bypass this maturation block by relieving the repressive
properties of PML/RARA on myeloid differentiation
genes.4
Alteration of transcription factors often seen in AMLs
such as RUNX1, GATA or CEBPA are commonly associat-
ed with mutations in tyrosine kinase receptors or other
important signaling molecules, such as RAS or FLT3.
Recent studies and the development of whole-genome
sequencing technologies have revealed a complex process
of leukemic transformation.5,6 These studies highlight the
importance of transcriptional regulators controlling gene
expression and differentiation, mutations affecting cell sig-
naling and, most recently, mutations affecting epigenetic
modifiers as co-operating factors in leukemic disease.  
It therefore appears that the path to cellular transforma-
tion can be a complex and multistep-process. In APL, sec-
ondary karyotypic lesions are often seen, with trisomy 8
being the most common. Trisomy 8 is also the most com-
mon unbalanced gain in AML in general.7,8 Interestingly,
the segment that is often gained carries the well-known
MYC proto-oncogene.9 MYC encodes a transcription fac-
tor controlling expression of downstream targets such as
cyclins, thereby promoting proliferation, but is also able to
limit cellular differentiation, including via deregulation of
the master regulator of myeloid differentiation C/EBPα.10
Importantly, MYC and C/EBPα expression require tight
regulation to maintain myeloid and stem cell
homeostasis.11 Previous analyses in our laboratory have
shown that cells characterized by a gain of MYC through
trisomy 8 display approximately 45% higher MYC RNA
levels. Using a PML/RARA transgenic model, we also
showed that MYC overexpression both accelerated the
development of leukemia and impaired myeloid cell mat-
uration, and that gain of MYC underlines the recurrent tri-
somy of this gene commonly seen in APL.9
Interestingly, TRIB1 is located contiguously to MYC on
chromosome 8, and is thus expected to be duplicated in
the chromosomal gain containing the MYC fragment. Not
surprisingly, overexpression of TRIB1 has been found in
several AML patients12 and TRIB proteins have been impli-
cated in AML pathogenesis.13 Initially the Tribbles gene
was identified in drosophila (dTribbles) and mammalian
TRIB genes are comprised of three human homologs:
TRIB1, TRIB2 and TRIB3.14 Supporting a role for TRIB1 in
disease initiation, murine recipients of hematopoietic
stem cells transduced with TRIB1 or TRIB2, but not TRIB3
developed AML and mediated COP1 ubiquitin ligase-
dependent C/EBPα degradation.15-17 This TRIB-mediated
degradation of C/EBPα was critical for TRIB-induced
AML, and possibly necessary for the maturation block
seen in AMLs. 
In APL, the PML/RARA fusion protein retains the DNA
binding domain of the endogenous RARA, therefore act-
ing as a chimeric transcription factor.18 By dimerizing and
associating with an altered set of co-factors the DNA bind-
ing specificity and repressive ability of the fusion protein
is expanded,19 a characteristic that is believed to play a key
role in the leukemogenic process. PML/RARA has been
shown to interact with key transcription factors of the
granulocytic differentiation program, such as PU.120 and
C/EBPα downregulation has been observed in PML/RARA
expressing cells,21,22 both events possibly participating in
the transformation process. Interestingly, TRIB1 has been
shown to co-localize with RARA/RXR leading to negative
regulation of the transcriptional activity of the complex,23
although the precise mechanism mediating this inhibition
is still unclear.
Given previous studies and clinical data implicating
PML/RARA, MYC and TRIB1 in AML and APL leukemo-
genesis, we aimed to investigate the co-operation of these
oncogenes in the development of leukemia. Using a retro-
viral bone marrow (BM) transduction and BM transplanta-
tion (BMT) approach to over-express MYC, TRIB1, or both
in wild type (Wt) or PML/RARA BM from transgenic ani-
mals, we characterized the resultant neoplasms arising in
the different groups. We found that MYC and TRIB1 co-
operated in AML, but that MYC alone was able to drive
APL development in the presence of PML/RARA. These
data indicate that PML/RARA and TRIB1 could share
redundant functions. We showed that TRIB1 (and TRIB2,
but not a mutant of TRIB1) prevents differentiation of
PML/RARA-expressing cells in the presence of ATRA,
which normally derepresses the fusion protein to allow
terminal maturation. We also showed that TRIB1 overex-
pression leads to sustained decreased C/EBPα protein lev-
els in these cells, providing an explanation for the inability
of these cells to respond to ATRA. Indeed, leukemias gen-
erated in secondary recipient animals transplanted with
PML/RARA+MYC+TRIB1+ leukemia were unresponsive
to ATRA, in contrast to the ATRA responsiveness of
PML/RARA+MYC+ leukemia.
Methods
Expression constructs and retrovirus production
The HA-tagged human MYC cDNA24 was subcloned into
MSCV-IRES-mCherry vector. Mouse Trib1 cDNA25 was subcloned
into MSCV-IRES-GFP (MigR1) vector. Mutant Trib1 (DC4)
expressed in MigR1 was previously published.26 Mouse Trib2
cDNA was subcloned into MSCV-IRES-GFP (MigR1) and MSCV-
IRES-NGFR (NGFR).15,17 For mouse BM transduction experiments,
BOSC23 packaging cell line was transfected with pCL-Eco and
retroviral expression plasmids, as previously described.9 For NB4
transduction experiments, HEK293T packaging cell line was trans-
fected with retroviral (pCGP, VSV-G) packaging vectors and retro-
viral expression plasmids. Viral supernatants (sups) were harvested
at 24-48 h post transfection.
Cell culture and transduction
NB4 cells were cultured in RPMI supplemented with 10% fetal
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bovine serum (FBS). Cells were transduced by spinoculation with
virus and 4 μg/mL Polybrene at 1290g for 90 mins at room tem-
perature (RT). Transduced cells were sorted by flow cytometry 48
h post transduction for GFP expression (MigR1, TRIB1, DC4) or
using anti-biotin beads (NGFR, TRIB2). Sorted cells were plated in
presence of 1 uM ATRA at a density of 0.05x106 cells/mL.
Bone marrow harvest, retroviral transduction and
transplantation
Donor animals (6-12 weeks old) were injected intraperitoneally
with 5-Fluorouracil (5 FU, 150 mg/kg animal) to enrich for hemo-
poietic stem and progenitor cells and push them into cycle for the
facilitation of retrovirus transduction. Leg and pelvic bones were
harvested and 1x106 white blood cells/mL plated into pre-stimula-
tion media (Myelocult M5300 Stemcell Technologies, 15% FBS,
10% of IL-3 and IL-6 conditioned medium, 0.4 mM of L-
Glutamine and 10 ng/mL of murine recombinant SCF). Two spin-
oculations were performed (at 4 h and 24 h after harvest), and cells
were injected retro-orbitally into lethally-irradiated 6-16-week old
recipients (3x105-1x106 cells/mouse).
Cytomorphology
Cytospins were prepared by harvesting 25,000 cells and slides
were stained with the Kwik-Diff staining kit (Thermo Scientific)
as per the manufacturer’s instructions. Chromatin condensation
and granularity was used to define differentiation on a Leica
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Figure 1. MYC and TRIB1 co-operate to initiate acute myeloid leukemia (AML), whereas
MYC alone combined with PML/RARA is able to drive acute promyelocytic leukemia
(APL). (A) Schematic representation of the in vivo experimental strategy used to assess
the selective advantage of MYC and/or TRIB1 in transforming wild-type (Wt) or
PML/RARA bone marrow (BM). Lethally-irradiated recipients were reconstituted with
transduced bone marrow, animals were monitored for disease development and the
arising neoplasm characterized. (B) Summary table combining all Wt leukemias and all
PML/RARA leukemias. As seen, no differences were observed in the mean or median
time to disease in AML or APL initiation. (C) Panels show the flow cytometry staining and
gating strategy used. (D) Phenotypic analysis of resultant leukemia in representative
examples of a Wt-MYC+TRIB1+, PML/RARA-MYC+ and PML/RARA-MYC+TRIB1+
leukemias. Panels show representative Wt-MYC+TRIB1+ (top left), PML/RARA-MYC+
(top right), and PML/RARA-MYC+TRIB1+ (bottom left) leukemias staining for CD45.1,
CD45.2, Gr-1 and c-Kit through the indicated gate of parental population; cytomorphol-
ogy of spleen, sternum, and liver from representative Wt-MYC+TRIB1+ (top left),
PML/RARA-MYC+ (top right) and PML/RARA-MYC+TRIB1+ (bottom left) leukemias show-





DM2000 and photographs taken on an Olympus DP70. A sample
of slides were blinded and reviewed by Dr Mike Leech,
Consultant Hematologist with expertise in diagnostic morphology
and there was 100% correlation with our findings. Paraffin
embedded sections were stained with hematoxylin & eosin
(H&E). Photographs were taken on a Nikon Eclipse 80i micro-
scope with a Nikon Digital Sight camera using NIS-Elements F2.30
or F4.30 software at a resolution of 2560 Å~ 1920.
Flow cytometry
A total of 10,000-50,000 cells were assessed by staining with
CD45.1, CD45.2, Gr1 (Ly6G), and c-Kit on a LSRFortessa (BD
Biosciences) or with CD15 (MMA) and CD11c (3.9) (eBioscience)
on a FACSCanto II (BD Biosciences). Dead cells were excluded by
DAPI staining (Sigma). Analysis was performed on FlowJo
(Treestar).
RNA extraction and real time q-PCR
Total RNA was extracted using RNeasy Mini Kit (QIAGEN) and
reverse transcribed with the High Capacity cDNA Reverse
Transcription Kit (Life Technologies). QPCR was performed using
Fast SYBR® Green Master Mix (Life Technologies) on a 7900HT
Fast Real-Time PCR System (Life Technologies). hENOX2, hABL
and hβ-2 microglobulin were used as internal controls and aver-
aged; relative mRNA levels were calculated using the 2-δδCT
method, and absolute mRNA levels calculated using the 2-δCT
method. Experiments were performed on technical triplicates and
biological duplicate samples. Details of primers are available in the
Online Supplementary Appendix.
Immunoblotting 
Lysates from cultured NB4 cells (50,000-150,000) +/- ATRA
were prepared by direct lysis in 2X SDS sample buffer. Antibodies
used were: anti-C/EBPα (Santa Cruz sc-61), anti-Actin (Sigma
Aldrich A5441). 
Animals
Mice were bred and maintained at University of California San
Francisco (UCSF) (USA) and Cardiff University (UK) and were
cared for  in accordance with Institutional Animal Care and Use
Committee guidelines. The recipients FVB/n CD45.1/45.2 mice
were generated by crossing FVB/n (CD45.1) to FVB/n CD45.2 con-
genic animals. hMRP8-PML/RARA mice have been previously
described.27 Fisher’s exact test was used to assess whether Wt and
PML/RARA leukemias were equivalent in their likelihood to
express TRIB1.
In vivo ATRA treatment of recipients transplanted with
PML/RARA leukemic cells
After one passage into recipient animals, resurrected cryopre-
served leukemic cells (2x106) of the PML/RARA-MYC+ and
PML/RARA-MYC+TRIB1+ phenotype were intravenously inject-
ed into unirradiated or sublethally irradiated (500 cGy) FVB/n mice
(n=4-5 per group in 2 independent experiments). Ten days post
injection, 10 mg 21-day release ATRA or placebo pellets
(Innovative Research of America) were implanted into the dorsal
neck scruff. Mice were sacrificed when moribund or upon veteri-
nary advice. Statistical significance was calculated using a log rank
test.
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Table 1. Summary table of the outcome of the in vivo leukemogenesis experiment, specifying the phenotype of the leukemia or cause of death
in the first column, disease latency (time to death column), mean time to disease, and input (donor) bone marrow (BM) specified in the last col-
umn.
Phenotype of arising leukemia Time to death Mean time to AML +/- Input BM
(days) SD (days)
Wt-MYC+TRIB1+ 88 Wt: PML/RARA (1:1)-MYC-TRIB1
Wt-MYC+TRIB1+ 92 Wt: PML/RARA (1:1)-MYC-TRIB1
Wt-MYC+TRIB1+ 109 Wt: PML/RARA (1:1)-MYC-TRIB1
Wt-MYC+TRIB1+ 119 Wt: PML/RARA (1:1)-MYC-TRIB1
Wt-MYC+TRIB1+ 126 149.8 +/- 53.6 Wt-MYC-TRIB1
Wt-MYC+TRIB1+ 154 Wt: PML/RARA (1:1)-MYC-TRIB1
Wt-MYC+TRIB1+ 167 Wt: PML/RARA (1:1)-MYC-TRIB1
Wt-MYC+TRIB1+* 176 Wt: PML/RARA (1:1)-MYC-TRIB1
Leukemic Wt-MYC+TRIB1+ 217 Wt-MYC-TRIB1
deaths Wt-MYC+TRIB1+ 250 Wt: PML/RARA (1:1)-MYC-TRIB1
PML/RARA-MYC+ 106 PML/RARA-MYC-TRIB1
PML/RARA-MYC+ 153 Wt: PML/RARA (1:1)-MYC-TRIB1
PML/RARA-MYC+ 162 154.6 +/- 28.9 Wt: PML/RARA (1:1)-MYC-TRIB1
PML/RARA-MYC+ 176 PML/RARA-MYC-TRIB1
PML/RARA-MYC+* 176 Wt: PML/RARA (1:1)-MYC-TRIB1
PML/RARA-MYC+TRIB1+ 109 Wt: PML/RARA (1:1)-MYC-TRIB1
PML/RARA-MYC+TRIB1+ 121 115 +/- 8.5 Wt: PML/RARA (1:1)-MYC-TRIB1
Myeloid leukemia, no phenotypic data 88 Wt: PML/RARA (1:1)-MYC-TRIB1
Abnormal tumor 27 Wt: PML/RARA (1:1)-MYC-TRIB1
Recipient-derived thymic tumor 153 PML/RARA-MYC-TRIB1
Recipient-derived thymic tumor 162 N/A Wt-MYC-TRIB1
No disease 260 PML/RARA-MYC-TRIB1
Non-leukemic No disease 260 PML/RARA-MYC-TRIB1
deaths No disease 267 Wt-MYC-TRIB1
No disease 272 Wt: PML/RARA (1:1)-MYC-TRIB1
AML: acute myeloid leukemia; SD: standard deviation; N/A: not applicable..*These two table entries represent one individual animal which developed leukemias of both the indi-
cated phenotypes. 
Bioinformatics analysis
GSE6891 and GSE12662 datasets reflect results on the
Affymetrix Human Genome U133 Plus 2.0 Array. Three TRIB1
probes are present: 202241_at, 239818_x_at, 235641_at. Signal
strength was more than 10-fold higher for 202241_at as compared
to the other probes and the results presented reflect this probe. 
P values were obtained using  Microsoft EXCEL t-test (two-tailed,
unequal variance). The MYC gene is represented in GSE6891 by
probe 202431_s_at. Correlations of MYC and TRIB1 expression
were assessed using Microsoft EXCEL, including calculation of R2
value.
Results and Discussion
In order to investigate if MYC and TRIB1 function co-
operatively in the context of myeloid leukemia, we uti-
lized a retroviral transduction system to concurrently
over-express MYC and Trib1 in 5-FU-treated murine BM
from Wt or PML/RARA transgenic animals. The
PML/RARA mouse model expresses a human PML/RARA
cDNA from the hMRP8 promoter cassette, which drives
transgene expression in myeloid cells.27 Three groups of
donor cells (PML/RARA, Wt, or a combination of Wt +
PML/RARA mixed in a 1:1 ratio) were transduced and
transplanted into lethally-irradiated recipients (n=5
PML/RARA donor group, n=4 Wt donor group, n=15 com-
bined donor group) (Figure 1A). In the combined donor
experiments, injected cells were comprised of all possible
combinations, including cells that lacked oncogene inte-
gration. With this approach, we anticipated that the cells
expressing all three oncogenes (PML/RARA, MYC and
TRIB1) would be most able to initiate leukemia. At disease
manifestation (or on day 260-272 at experiment termina-
tion), BM from these animals was harvested and analyzed
by flow cytometry to look at chimerism and characteriza-
tion of the arising neoplasm. Every leukemia which arose
from the Wt donor BM expressed both MYC and TRIB1,
confirming that these oncogenes co-operate and co-
express to drive AML transformation in this transplant
model (Table 1, red color-coded in column 2). In contrast,
leukemias originating from PML/RARA-expressing donor
BM displayed a different phenotype, with 5 leukemias
expressing MYC only (Table 1, green color-coded in col-
umn 2), and only 2 leukemias expressing both MYC and
TRIB1 (Table 1, blue color-coded in column 2). With
regard to the non-leukemic mice in our study, at the time
of experiment termination, 4 of 24 recipient mice had
failed to develop disease and 3 others were identified as
bearing recipient-derived malignancies likely due to irradi-
K. Keeshan et al.
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Figure 2. TRIB1 expression is decreased in
human acute promyelocytic leukemia (APL)
and does not correlate with MYC expression. (A)
TRIB1 transcript levels in 21 cases of human
APL are compared to levels in 440 cases of
human non-APL acute myeloid leukemia (AML).
Midlines represent median values, boxes repre-
sent 25th-75th percentiles, whiskers represent
range of all values. TRIB1 levels are lower in APL
than in non-APL AML (P<0.001). (Dataset
reported values in log2 scale of GSE6891 have
been transformed to linear values for clarity.) (B)
TRIB1 values rise with maturation from human
normal CD34 (n=5) to normal promyelocytes
(n=5), but are low in human APL (n=14).
Individual values are shown. [Intensity signal on
arrays were scaled differently in the GSE6891
and GSE12662 datasets resulting in the differ-
ent relative expression scales in (A) and (B)]. (C)
Correlation plots of TRIB1 expression and MYC
expression in GSE6891 for 461 AMLs, including
APL, as well as for AMLs with isolated trisomy 8
(+8, n=20), AMLs with normal karyotype (NK,
n=187), and APL alone (n=21). Trendlines are
shown but R2 <0.5 for each of the comparisons.
[Dataset log2 scale GSE6891 values were
graphed for these comparisons; in contrast to
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Figure 3. TRIB1 overexpression blocks the ATRA-mediated differentiation of NB4 cells. (A) NB4 cells were transduced with control MigR1, MigR1-TRIB1, and MigR1-
DC4 (Trib1 mutant unable to degrade C/EBPα), sorted and treated with 1 μM ATRA for six days and cell morphology assessed by manual differential counts. (B)
Representative cell morphology at day 0 and day 6. (C) Flow cytometry analysis of CD15 and CD11c expression in vehicle control (VC top) and ATRA treated trans-
duced NB4 cells at day 6. (D) QPCR analysis of: exogenous Trib1 (top) and endogenous TRIB1 (bottom) in MigR1 and MigR1-TRIB1 transduced NB4 cells treated
with ATRA at the indicated time points. Top graph depicts absolute gene expression relative to internal controls. Bottom graphs depict relative gene expression nor-
malized to MigR1-control at day 0. (E) QPCR analysis of G-CSFR in MigR1, MigR1-TRIB1, and MigR1-DC4 transduced NB4 cells treated with ATRA at the indicated
time points. Graphs depict relative gene expression normalized to MigR1-control at day 0. Significance determined by one-way ANOVA and Bonferroni post test.
*P<0.05; **P<0.01. (F) Western blot analysis for C/EBPα in direct lysis samples prepared from NB4 cells transduced with control MigR1, MigR1-TRIB1, and MigR1-







ation. In the presence of PML/RARA, the dominant
leukemic phenotype was MYC co-expression alone, as
opposed to the Wt setting where MYC and TRIB1 were
always co-expressed to drive leukemia. It is highly unlike-
ly that this result was due to chance. If the selective pres-
sure to express TRIB1 had been equivalent in Wt and
PML/RARA-expressing BM, then we would have expect-
ed equal proportions of Wt and PML/RARA leukemias to
express TRIB1. In fact, the observed result of TRIB1
expression in 10 of 10 Wt leukemias but only 2 of 7
PML/RARA leukemias indicates that selection for TRIB1
was indeed abrogated by the presence of PML/RARA
(P=0.003). Of note, this was not a result of different TRIB1
levels in the Wt and PML/RARA leukemias as similar
transduction levels were obtained in the groups (data not
shown). To our surprise, transduced PML/RARA marrows
did not outcompete transduced wild-type marrows in the
combined donor experiments, further supporting the idea
that PML/RARA and TRIB1 did not co-operate in
leukemia initiation. When looking at all the Wt or
PML/RARA leukemias combined (Figure 1B), we do not
observe statistically significant differences in terms of
numbers or time to disease, although a wider range of
latencies was observed for the Wt leukemias. The median
latency to disease observed in Wt and PML/RARA
leukemias was 140 and 153 days, respectively, suggesting
that additional events are likely necessary to complete the
transformation process, which could further explain why
some recipients did not develop disease within the time-
frame of the experiment. Morphologically, Wt and
PML/RARA leukemias resembled each other and were
characterized by the expansion of immature myeloid cells.
Flow cytometry analysis and histology staining from a
representative Wt-MYC+TRIB1+, PML/RARA-MYC+
and a PML/RARA-MYC+TRIB1+ leukemia are shown in
Figure 1D, showing similar leukemic cell organ infiltration
and morphology of the indicated leukemias. Flow cyto-
metric immunophenotyping confirmed an immature
myeloid character, with some variation in levels of expres-
sion of KIT and Gr1. Thus, MYC and TRIB1 co-expression
were able to drive myeloid leukemia, similar to leukemias
driven by PML/RARA and MYC co-expression. 
We hypothesized that if TRIB1 levels play a pathogenic
role in some AMLs, but not in APL, that APL might show
lower TRIB1 expression than other AMLs. Using a pub-
lished dataset (GSE689128) we compared TRIB1 transcript
levels in 21 APLs to those seen in 440 non-APL AMLs. On
average, APLs expressed less than 50% the level of TRIB1
K. Keeshan et al.
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Figure 4. TRIB1 overexpression abrogates ATRA response  in vivo. (A) Schematic representation of the in vivo experimental strategy to assess ATRA response in
PML/RARA+MYC+ versus PML/RARA+MYC+TRIB1+ leukemias (n=10 each group). Recipient animals were either unirradiated or sublethally-irradiated and trans-
planted with PML/RARA-MYC+ or PML/RARA-MYC+TRIB1+ leukemias. (B) Kaplan-Meier survival curves of transplanted animals treated with placebo or ATRA pellet
implantation. ATRA is able to extend survival of PML/RARA+MYC+ but not PML/RARA+MYC+TRIB1+ secondary transplanted mice. Using the log rank (Mantel-Cox)
test for each group, PML/RARA-MYC+: placebo versus ATRA P<0.0001 (longer survival with ATRA; PML/RARA-MYC+TRIB1+: placebo versus ATRA; P<0.05 (shorter
survival with ATRA).  
A
B
present in non-APL AMLs  (P<0.001) (Figure 2A). In order
to assess if this simply reflected the normal expression lev-
els in promyelocytes as compared to less mature myeloid
blasts, we examined TRIB1 levels in a published dataset
(GSE1266229) that includes normal CD34 cells, normal
promyelocytes and APLs. TRIB1 increases 5-fold with
maturation from normal CD34 cells to normal promyelo-
cytes, indicating that the low levels in APL as compared to
other non-APL AMLs is not simply a reflection of cell mat-
uration. Furthermore, in this dataset, APLs expressed
much lower levels of TRIB1 than do normal promyelo-
cytes (>4 fold decrease;  P<0.003) (Figure 2B). While recog-
nizing that mRNA levels may not reflect protein levels,
these results are compatible with the idea that TRIB1 does
not contribute to the pathogenesis of APL. We also exam-
ined  the published dataset of 461 AMLs (including 21
APLs) to evaluate whether there is a correlation between
increased TRIB1 transcripts and increased MYC tran-
scripts, which would suggest co-selection for expression.
Although our data in mice show that MYC and TRIB1 can
co-operate in AML, in the human dataset there was no sig-
nificant correlation between TRIB1 levels and MYC levels
in AML as a whole, as well as no significant correlation in
the normal karyotype (n=187), +8 (n=20), and APL (n=21)
subsets  (R2 <0.5 for these four comparisons) (Figure 2C).
Our in vivo leukemogenesis experiments showed that
TRIB1 overexpression does not co-operate with
PML/RARA for disease initiation but rather appears to
phenocopy the PML/RARA-induced disease in the context
of MYC co-expression. These results raise the possibility
that PML/RARA and TRIB1 share overlapping functions
or have redundant functions in leukemic transformation,
thereby explaining the lack of selective advantage for cells
to express PML/RARA, MYC and TRIB1 concomitantly.
C/EBPα is a key myeloid transcription factor shown to be
a target of both PML/RARA and TRIB family members,
potentially representing the common target of the two
oncogenes in our model. To test this hypothesis, we used
an established in vitro system in which PML/RARA-
expressing APL cells are induced to terminally differentiate
by exposure to all-trans retinoic acid (ATRA). As a master
regulator of granulocyte maturation, activation of C/EBPα,
C/EBPβ30 and its downstream targets is mandatory to
bypass the maturation block in these cells, which ATRA
can circumvent by directly targeting PML/RARA.
Therefore, we hypothesized that over-expressing TRIB
proteins in PML/RARA-expressing cells might abrogate
the differentiating effect of ATRA due to C/EBPα inhibi-
tion or degradation. NB4 cells transduced with control,
TRIB1 or TRIB1 mutant (DC4) unable to bind and degrade
C/EBPα26 expressing retroviruses were cultured in pres-
ence of ATRA for six days to induce myeloid differentia-
tion. NB4 cells differentiated after six days in ATRA, as
seen by loss of nucleoli, maturation/condensation of the
chromatin and granularity, and CD15 and CD11c surface
marker expression, indicating that the maturation block
had been bypassed following targeting of PML/RARA by
ATRA (Figure 3A-C; MigR1 controls). TRIB1 overexpres-
sion was able to block ATRA-induced differentiation and
this was lost upon overexpression of mutant TRIB1 (DC4)
(Figure 3A-C). These data indicate that TRIB1 abrogates
ATRA-induced terminal differentiation and suggest the
mechanism is via C/EBP degradation. 
Using primers specific for endogenous human TRIB1,
we observed that ATRA treatment (which degrades
PML/RARA) up-regulated TRIB1 in NB4 cells (Figure 3D).
In combination with the finding (see above) that TRIB1
transcript levels are lower in human APL than they are in
normal human promyelocytes, it appears possible
PML/RARA may suppress TRIB1 expression. Although
we have not investigated the mechanism for low endoge-
nous TRIB1 levels in APL cells, PML/RARA suppression of
TRIB1 may be permissive for increased C/EBP activity in
response to ATRA and therefore permissive for matura-
tion beyond the promyelocyte stage. NB4 cell transduc-
tion with TRIB1 expressing vectors resulted in significant
expression of exogenous TRIB1 (detected using mouse
TRIB1 specific primers) and, of note, there was no increase
in endogenous TRIB1 in response to ATRA when exoge-
nous TRIB1 was present (Figure 3D). 
To further investigate TRIB-mediated block of ATRA-
induced differentiation via C/EBPα, we assessed the gene
expression of a C/EBPα-dependent target important for
granulocytic maturation, G-CSF receptor (G-CSFR).31
G-CSFR gene expression levels increased over time in the
control groups, as expected, which was blocked upon
expression of TRIB1 and lost upon overexpression of
mutant TRIB1 (DC4) (Figure 3E), demonstrating that
expression of TRIB1 protein inhibits a C/EBPα-dependent
target gene important for driving the myeloid maturation
program. To confirm that the inhibitory phenotypic and
transcriptional activities of TRIB proteins are mediated via
C/EBP protein inhibition, we assessed C/EBPα protein lev-
els. Expression of TRIB1 attenuated ATRA-induced
C/EBPα protein expression and this was lost upon overex-
pression of mutant TRIB1 (DC4) (Figure 3F). We also
assessed C/EBPβ protein levels and found that TRIB1
attenuated ATRA-induced C/EBPβ protein levels but not
with the same impact as on C/EBPα protein expression
(Online Supplementary Figure S1A). Similarly, the overex-
pression of TRIB2 in NB4 cells blocked ATRA-induced dif-
ferentiation assessed by morphology and G-CSFR gene
expression, and abrogated the ATRA-mediated induction
of C/EBPα, C/EBPβ and PU.1 transcription factors (Online
Supplementary Figure S1B-D). These data provide strong
evidence that TRIB1 or TRIB2 overexpression prevents
ATRA-induced differentiation of APL cells via the inhibi-
tion of C/EBPα. 
To further study the clinical relevance of TRIB1 expres-
sion in APL, we investigated ATRA (or placebo) response
in vivo in recipient animals inoculated with PML/RARA-
MYC+ compared to PML/RARA-MYC+TRIB1+
leukemia. Leukemias generated in our initial leukemogen-
esis experiment (Figure 1) were tested (see Figure 4A for
details of the experimental strategy) in two independent
experiments. Results of these experiments were concor-
dant and the combined results are shown (Figure 4B).
Significantly, the response of the leukemias to ATRA treat-
ment was markedly different. ATRA treatment significant-
ly delays disease progression and extends median survival
from 31 to 53 days (P<0.0001) in recipients of PML/RARA-
MYC+ leukemias compared to placebo treated controls, as
expected. However, ATRA did not extend survival in mice
injected with PML/RAR-MYC+TRIB1+ leukemia. These
results show that TRIB1 expression abrogates ATRA
response in vivo confirming our in vitro findings. Our data
indicate that TRIB1 expression provides critical oncogenic
functions preventing APL cells from responding to ATRA
therapy, presumably via repression of C/EBPα.
To conclude, in this study we aimed to investigate the
MYC, TRIB1 and PML/RARA co-operation in APL and AML
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co-operation of MYC and TRIB1 in the pathogenesis of
AML and APL, two genes located on a contiguous frag-
ment of chromosome 8 in humans. Given the common
gain of the MYC/TRIB1-containing segment in AMLs, we
hypothesized that TRIB1 could also play an important role
in leukemic transformation, including for APL. Using a
retroviral transduction model of in vivo leukemogenesis,
we found that both TRIB1 and MYC oncogenes co-oper-
ate to initiate AML, but that in most cases, MYC is suffi-
cient to accelerate APL leukemogenesis. C/EBPα downreg-
ulation is an overlapping function of PML/RARA and
TRIB1, and this common feature explains the lack of selec-
tive leukemic outgrowth for clones expressing both these
oncogenes. The responsiveness to ATRA treatment was
severely impaired by the expression of TRIB1, a pheno-
type observed both in vitro and in vivo. Overall, our results
provide critical information about the role of TRIB1 in
leukemogenesis and responsiveness to ATRA treatment.
Our data support a role for PML/RARA in altering C/EBPα
and C/EBPβ in APL leukemogenesis and provide strong
genetic evidence for a key role of C/EBP family members
in myeloid leukemias beyond those with mutations in or
methylation of the CEBPA gene. 
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